Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

MRCK alpha Inhibitors

MRCK alpha inhibitors are a class of chemical compounds that specifically target and inhibit the activity of myotonic dystrophy kinase-related Cdc42-binding kinase alpha (MRCKα). MRCKα is a member of the AGC kinase family, which includes protein kinases involved in various cellular processes such as cell proliferation, survival, and cytoskeletal reorganization. MRCKα, in particular, is known to play a crucial role in the regulation of the actin cytoskeleton, which is essential for maintaining cell shape, motility, and adhesion. By modulating actin dynamics, MRCKα influences the formation of cellular structures like lamellipodia and filopodia, which are extensions of the cell membrane that facilitate cell movement and interaction with the surrounding environment. The inhibition of MRCKα disrupts these processes, leading to alterations in cell morphology and a reduction in cell motility. Chemically, MRCK alpha inhibitors are diverse and can include small molecules that have been structurally optimized to interact specifically with the kinase domain of MRCKα, blocking its enzymatic activity. These inhibitors often achieve specificity by fitting into the ATP-binding pocket of the kinase, thereby preventing ATP from binding and subsequently halting the phosphorylation of downstream substrates. The structural diversity of MRCK alpha inhibitors allows for the fine-tuning of their binding affinity and selectivity towards MRCKα over other kinases, reducing off-target effects and enhancing their inhibitory potency. The development and characterization of MRCK alpha inhibitors also involve extensive biochemical and biophysical studies to understand their interaction mechanisms at the molecular level, including the identification of key binding residues and conformational changes induced upon binding. Such inhibitors are valuable tools in the study of MRCKα's role in cellular processes, providing insights into the molecular pathways governed by this kinase and contributing to our understanding of cytoskeletal regulation and its broader implications in cell biology.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$137.00
$512.00
7
(1)

ML141 is a selective small molecule inhibitor of CDC42 that also affects CDC42BPA. It binds to the CDC42 effector-binding domain and disrupts CDC42 interactions with downstream effectors, including CDC42BPA.

ZCL278

587841-73-4sc-507369
10 mg
$115.00
(0)

While primarily known as a CDC42 inhibitor, ZCL278 may also influence CDC42BPA due to the shared regulatory pathways between CDC42 and CDC42BPA.

CASIN

425399-05-9sc-397016
10 mg
$460.00
1
(0)

Although it primarily targets Rac1 and Cdc42, CASIN might also affect CDC42BPA due to the functional overlap between CDC42 and related GTPases.